NCT02595905: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

NCT02595905
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have either triple negative breast cancer or have tumors that are BRCA+; Patients must have had at least 1 prior cytotoxic regimen for metastatic disease; Patients with progressing brain metastases can have received up to 3 prior lines of cytotoxic chemotherapy for metastatic disease
Exclusions: 
https://clinicaltrials.gov/show/NCT02595905

Comments are closed.

Up ↑